Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion

Life Sciences

Volumn 94, Issue 2, 2014, Pages 115-121

  Tanaka, Hirotsugu ^a   Yoshida, Shigeru ^a   Minoura, Hideaki ^a   Negoro, Kenji ^a   Shimaya, Akiyoshi ^a   Shimokawa, Teruhiko ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Diabetes; GPR40; Insulin secretion; OGTT

Indexed keywords

ANTIDIABETIC AGENT; AS 2575959; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; SITAGLIPTIN; SODIUM[6 [[4 (3,4 DIHYDROXYBUTOXY) 2,2',6' TRIMETHYL(1,1' BIPHENYL) 3 YL]METHOXY] 3H SPIRO(1 BENZOFURAN 2,1' CYCLOPROPAN) 3 YL]ACETATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MONOTHERAPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

MUS;

DIABETES; GPR40; INSULIN SECRETION; OGTT;

ACETATES; ANIMALS; BLOOD GLUCOSE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG SYNERGISM; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; MALE; MICE; MICE, INBRED ICR; MICE, OBESE; PYRAZINES; RECEPTORS, G-PROTEIN-COUPLED; SPIRO COMPOUNDS; TRIAZOLES;

EID: 84891829171     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2013.11.010     Document Type: Article

References (31)

1. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
2. M. Abe, K. Okada, T. Maruyama, N. Maruyama, and K. Matsumoto Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis Expert Opin Pharmacother 11 2010 169 176
3. R. Arechavaleta, T. Seck, Y. Chen, K.J. Krobot, E.A. O'Neill, and L. Duran et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial Diabetes Obes Metab 13 2011 160 168
4. C.P. Briscoe, M. Tadayyon, J.L. Andrews, W.G. Benson, J.K. Chambers, and M.M. Eilert et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids J Biol Chem 278 2003 11303 11311
5. C.F. Burant, P. Viswanathan, J. Marcinak, C. Cao, M. Vakilynejad, and B. Xie et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial Lancet 379 2012 1403 1411
6. B. Charbonnel, H. Steinberg, E. Eymard, L. Xu, P. Thakkar, and V. Prabhu et al. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial Diabetologia 56 2013 1503 1511
7. E. Christiansen, C. Urban, N. Merten, K. Liebscher, K.K. Karlsen, and A. Hamacher et al. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes J Med Chem 51 2008 7061 7064
8. A.S. Dobs, B.J. Goldstein, P. Aschner, E.S. Horton, G.E. Umpierrez, and L. Duran et al. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes J Diabetes 5 2013 68 79
9. D.J. Drucker Enhancing incretin action for the treatment of type 2 diabetes Diabetes Care 26 2003 2929 2940
10. D.J. Drucker Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls Diabetes 62 2013 3316 3323
11. S. Edfalk, P. Steneberg, and H. Edlund Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion Diabetes 57 2008 2280 2287
12. S.S. Engel, D.E. Williams-Herman, G.T. Golm, R.J. Clay, S.V. Machotka, and K.D. Kaufman et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis Int J Clin Pract 64 2010 984 990
13. 2 + channel and link to insulin release Am J Physiol Endocrinol Metab 289 2005 E670 E677
14. G.A. Herman, A. Bergman, C. Stevens, P. Kotey, B. Yi, and P. Zhao et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes J Clin Endocrinol Metab 91 2006 4612 4619
15. Y. Itoh, Y. Kawamata, M. Harada, M. Kobayashi, R. Fujii, and S. Fukusumi et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40 Nature 422 2003 173 176
16. Y. Iwamoto, N. Tajima, T. Kadowaki, K. Nonaka, T. Taniguchi, and M. Nishii et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial Diabetes Obes Metab 12 2010 613 622
17. K. Kaku, T. Araki, and R. Yoshinaka Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes Diabetes Care 36 2013 245 250
18. D.C. Lin, J. Zhang, R. Zhuang, F. Li, K. Nguyen, and M. Chen et al. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents PLoS One 6 2011 e27270
19. J. Luo, G. Swaminath, S.P. Brown, J. Zhang, and Q. Guo et al. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents PLoS One 7 2012 e46300
20. A. Melander, H.E. Lebovitz, and O.K. Faber Sulfonylureas. Why, which, and how? Diabetes Care 13 Suppl. 3 1990 18 25
21. K. Nagasumi, R. Esaki, K. Iwachidow, Y. Yasuhara, K. Ogi, and H. Tanaka et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice Diabetes 58 2009 1067 1076
22. M.A. Pfeifer, J.B. Halter, R.G. Judzewitsch, J.C. Beard, J.D. Best, and W.K. Ward et al. Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man Diabetes Care 7 Suppl. 1 1984 25 34
23. M. Prentki, K. Tornheim, and B.E. Corkey Signal transduction mechanisms in nutrient-induced insulin secretion Diabetologia 40 Suppl. 2 1997 S32 S41
24. Y. Sakamoto, J. Oyama, H. Ikeda, S. Kuroki, S. Gondo, and T. Iwamoto et al. Effects of sitagliptin beyond glycemic control: focus on quality of life Cardiovasc Diabetol 12 2013 35
25. T. Shiba Improvement of insulin resistance by a new insulin secretagogue, nateglinide - analysis based on the homeostasis model Diabetes Res Clin Pract 62 2003 87 94
26. C.P. Tan, Y. Feng, Y.P. Zhou, G.J. Eiermann, A. Petrov, and C. Zhou et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice Diabetes 57 2008 2211 2219
27. H. Tanaka, S. Yoshida, H. Oshima, H. Minoura, K. Negoro, and T. Yamazaki et al. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion J Pharmacol Exp Ther 346 2013 443 452
28. S.J. Taylor, H.Z. Chae, S.G. Rhee, and J.H. Exton Activation of the beta 1 isozyme of phospholipase C by alpha subunits of the Gq class of G proteins Nature 350 1991 516 518
29. Y. Tsujihata, R. Ito, M. Suzuki, A. Harada, N. Negoro, and T. Yasuma et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats J Pharmacol Exp Ther 339 2011 228 237
30. Y. Xiong, G. Swaminath, Q. Cao, L. Yang, Q. Guo, and H. Salomonis et al. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1 Mol Cell Endocrinol 369 2013 119 129
31. Z. Yu, and T. Jin New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1) Cell Signal 22 2010 1 8